Why Şahin and Türeci Are Starting Again: The Founder's Dilemma After a Global Breakthrough
- Jörn Menninger
- 5 days ago
- 5 min read
Updated: 14 hours ago
Founders who reach platform-scale success face a structural problem: the company they built can no longer execute the science they want to do. Şahin and Türeci's planned 2026 spin into a new mRNA company is the engineered answer — separate frontier research from commercial discipline, retain agency, keep economic exposure through BioNTech's planned minority stake. It is the rarest move in European deep tech because it requires founders who own the cap table to design it.
Introduction
The 10 March 2026 BioNTech announcement reads, on first pass, like a leadership transition story: founders step out of management by end-2026, new mRNA company forms, BioNTech contributes technology in exchange for a minority stake. Underneath the corporate language is a much rarer phenomenon. Şahin and Türeci are restarting at the front of their second curve, on their own terms, while the platform they built continues to execute.
Executive summary
The "founder's dilemma" at platform scale is not "should I leave?" — it is "how do I keep doing the science that built the company without dragging the company into research-stage risk?" Şahin and Türeci's answer is structural: a new independent mRNA company, founder-led, with BioNTech as a minority stakeholder and technology contributor. The structure preserves three things European founders typically lose at scale — agency, focus, and economic alignment — and it does so through capital architecture rather than charisma.
• The transition is structural, not emotional — engineered through equity, technology contribution, and economic consideration.
• BioNTech retains minority stake + planned milestones and royalties from new co.; new co. retains founder leadership and frontier focus.
• This pattern requires founders who own enough of the cap table to design the second act — most European deep-tech founders cannot.
• The market reaction (BioNTech ADRs fell sharply on announcement) reflects investor uncertainty, not pipeline change.
• The DACH ecosystem lesson: found with cap-table architecture in mind, not just product-market fit.
The dilemma at platform scale
Founder-led platform companies face a structural tension as they mature. The science that justified the bet — frontier mRNA, in BioNTech's case — naturally moves toward stages of risk that institutional shareholders cannot fund efficiently. Late-stage clinical execution requires operational discipline, regulatory predictability, and quarterly investor stewardship. Frontier research requires patience, optionality, and the willingness to be wrong publicly. The same company cannot optimize for both.
Most US biotech solves this by replacing the founder. Most European deep tech solves it by suffocating the founder until the science slows. The BioNTech founders chose a third option: separate the company. By spinning a new founder-led mRNA entity, they let BioNTech sharpen its multi-product oncology execution while preserving their own ability to do early-stage science with full agency.
Why this is rare in European deep tech
The structural move requires three preconditions that are typically absent in European deep tech. First, the founders must control enough of the cap table to negotiate a clean spin. Second, the company must have a balance sheet strong enough to absorb a planned minority-stake outcome rather than a sale. BioNTech's ~€17.2 billion in cash and security investments at year-end 2025 matters here. Third, the founders must be willing to start at the front of a new curve when they could comfortably retire.
Reading the market reaction
BioNTech ADRs fell sharply on 10 March 2026, with Reuters reporting the largest one-day drop in roughly 18 months. The drop is best read as an investor-confidence reaction to founder departure during a critical late-stage oncology execution window — not as a re-rating of the underlying pipeline guidance. BioNTech reaffirmed its 2026 outlook in the same release: revenues from the BMS oncology collaboration broadly in line with 2025, modest decline in Comirnaty revenues, and 15 ongoing Phase 3 oncology trials by year-end. The pipeline is intact; the leadership question is what investors are pricing.
What this means for DACH founders today
The actionable lesson from Şahin and Türeci's move is simple to state and hard to execute: design your cap table for the founder you will be in fifteen years, not the founder you are at incorporation. If your equity dilution path forecloses the option to spin a second company while keeping minority economic exposure to the first, you have given up future agency in exchange for short-term capital. Most early-stage European founders do exactly this without realizing it. The Strüngmann anchor in BioNTech is the structural reason this option remained open.
FAQ
Why are Şahin and Türeci leaving BioNTech management?
They are not "leaving" in the conventional sense. They are transitioning out of executive roles by end-2026 to lead a new independent mRNA company, with BioNTech as a planned minority stakeholder and technology contributor.
Will the new company compete with BioNTech?
The disclosed structure suggests deliberate non-overlap: BioNTech sharpens its multi-product oncology execution; the new co. pursues next-generation mRNA innovations.
How can a founder pair design a transition like this?
It requires three preconditions: cap-table control sufficient to negotiate a clean spin, a balance sheet strong enough to support a long-horizon minority position, and a willingness to start a new company at the front of a new curve.
Should investors worry about BioNTech's pipeline after the founders leave?
BioNTech reaffirmed its 2026 guidance in the same announcement.
People and money behind this story
The "founder's dilemma at platform scale" only resolves cleanly when four sets of relationships are already in place.
Founders → entity (current and earlier). Uğur Şahin and Özlem Türeci co-founded BioNTech in Mainz in 2008 and previously co-founded Ganymed Pharmaceuticals in 2001 (acquired by Astellas Pharma in 2016 for up to €1.28 billion). The 2026 spinout is the third operating company they will lead together — by design, not by accident.
Co-founders. Şahin and Türeci are married and have co-founded every operating company in the cluster together. Andreas and Thomas Strüngmann, the identical twin brothers behind the BioNTech anchor investment, are themselves a co-founder pair: Hexal (1986) and Eon Labs (1995 acquisition).
Investors → investing entity. Andreas Strüngmann and Thomas Strüngmann each act as a co-controller of Athos Service, the family office that holds their post-Hexal portfolio. The mechanics of the 2026 BioNTech transition — minority stake, technology contribution, milestones, royalties — are only viable because that investing entity has the patience for a 10-15 year holding period.
Investing entity → portfolio companies. Athos Service holds the BioNTech anchor position (since 2008), plus positions in Immatics and Tubulis. The Gates Foundation's 2019 ~$55M investment in BioNTech (for HIV and tuberculosis programs) was the pre-COVID validation that the mRNA platform itself, not just the COVID vaccine, was institutionally credible.
Related on Startuprad.io
If you are a B2B technology company looking to enter or scale in the DACH region, the Startuprad.io network connects you with founders, investors, and strategic partners across Germany, Austria, and Switzerland. Become a partner to access introductions, distribution, and ecosystem visibility.
About the author
Joern "Joe" Menninger is the founder and host of Startuprad.io, the most-syndicated startup podcast covering the DACH region (Germany, Austria, Switzerland). With more than 740 episodes and over 1 million streams, Startuprad.io has hosted founders, investors, and policymakers shaping the European tech ecosystem since 2014. Connect on LinkedIn.
Comments